- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04317833
A Study of SSS17 in Healthy Subjects
A Single Dose Escalation Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of SSS17 in Chinese Healthy Subject
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures.
The improved Fibonacci dose escalation design will be implemented. The protocol specifies 10 mg, oral, one time for the first cohort without placebo control. Successive cohorts will be given doses up to 540 mg with placebo parallel control. Only no observation meets the criteria under stop rules, dose will escalate to the next higher level.
The study will be divided into 2 stages: 1st period (fast) and 2nd period(fed).
First period (fast): Subjects will be allocated 1:4 to receive placebo or SSS17, which will be administered by oral route. At each dose, tolerability, safety, PK and PD characteristics will be investigated.
Second period (fed): in order to investigate the effects of food on PK and PD of SSS17. Subjects in one cohort will be administered again after meal on Day15. The accurate dose will be adjusted according to the findings in 1st period (fast)
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hongzhou Lu, Ph.D
- Phone Number: (021)37990333-5278
- Email: jigouban@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201203
- Shanghai Public Health Clinical Center
-
Contact:
- Hongzhou Lu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body weight≥50 for male or ≥45 for female, and BMI between 19.0-26.0 kg/m2
- Good general health as determined by the investigator based on medical history, physical examination, vital signs, 12-lead ECG, clinical laboratory tests and B-type ultrasound test.
- Participants of reproductive potential must agree to utilize reliable methods of contraception from screening to 6 months after the last administration of the study intervention. No plan for sperm (or egg) donation or pregnancy.
- Understand and sign the informed consent.
- Ability to understand and follow study-related instruction
Exclusion Criteria:
- A known allergy to any component of the SSS17 formulation, or allergy history of two kinds of drugs or food
- Medical history or conditions of digestive system.
- Female volunteers who are pregnant, menstrual, lactating or menopause with hormone therapy.
- Eyes diseases, including diabetic retinopathy, age-related macular degeneration.
- Vascular anomalies.
- Drug, alcohol or nicotine addiction.
- Blood donation or bleeding (more than 200 ml). Experience of treatment with EPO or blood transfusion.
- Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
- Abnormal results in test of TIBC, serum iron or ferritin
- Acute diseases before administration.
- Other situations that the researcher believes may affect validity judgment or are not suitable for participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation SSS17
Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Placebo Comparator: Escalation matching Placebo
Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
|
matched placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AEs
Time Frame: up to Day14 or 29
|
assessment AEs by frequency, severity
|
up to Day14 or 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of SSS17
Time Frame: [ up to 48 hours post-dose]
|
Plasma samples will be collected and Cmax will be assessed.
|
[ up to 48 hours post-dose]
|
Area under the concentration-time curve (AUC) of plasma concentration of SSS17
Time Frame: [ up to 48 hours post-dose]
|
Plasma samples will be collected and the AUC from zero to infinity will be assessed.
|
[ up to 48 hours post-dose]
|
Time-to-Cmax (Tmax) of SSS 17
Time Frame: [ up to 48 hours post-dose]
|
Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve.
|
[ up to 48 hours post-dose]
|
Elimination terminal half-life (t1/2) of SSS17
Time Frame: [up to 48 hours post-dose]
|
Plasma samples will be collected and the t1/2 will be assessed.
|
[up to 48 hours post-dose]
|
Total amount of SSS17 excreted in urine over 24 hours (Ae0-24)
Time Frame: only for one cohort (up to 72 hours post-dose)
|
Urine sample will be collected at pre-specified intervals and Ae0-24 will be assessed.
|
only for one cohort (up to 72 hours post-dose)
|
Fraction of SSS17 excretion during each collection interval (Fe0-24)
Time Frame: only for one cohort (up to 72 hours post-dose)
|
Urine sample will be collected at pre-specified intervals and Fe0-24 will be assessed.
|
only for one cohort (up to 72 hours post-dose)
|
Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)
Time Frame: only for one cohort (up to 72 hours post-dose)
|
Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed.
|
only for one cohort (up to 72 hours post-dose)
|
Fraction of SSS17 excretion during each collection interval (Fe0-72)
Time Frame: only for one cohort (up to 72 hours post-dose)
|
Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed.
|
only for one cohort (up to 72 hours post-dose)
|
Renal clearance (CLR) of SSS17
Time Frame: only for one cohort (up to 72 hours post-dose)
|
Urine sample will be collected at pre-specified intervals and CLR will be assessed.
|
only for one cohort (up to 72 hours post-dose)
|
EPO concentrations
Time Frame: up to 168 hours post-dose.
|
Change of EPO concentrations from baseline following SSS17
|
up to 168 hours post-dose.
|
VEGF concentrations
Time Frame: up to 168 hours post-dose.
|
Change of VEGF concentrations from baseline following SSS17
|
up to 168 hours post-dose.
|
Change of RTC from baseline
Time Frame: up to 168 hours post-dose.
|
Change of RTC from baseline following SSS17
|
up to 168 hours post-dose.
|
Change of RBC from baseline
Time Frame: up to 168 hours post-dose.
|
Change of RBC from baseline following SSS17
|
up to 168 hours post-dose.
|
Change of Hgb from baseline
Time Frame: up to 168 hours post-dose.
|
Change of Hgb from baseline following SSS17
|
up to 168 hours post-dose.
|
Change of hepcidin from baseline
Time Frame: up to 168 hours post-dose.
|
Change of serum hepcidin concentrations from baseline following SSS17
|
up to 168 hours post-dose.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYSS-SSS17-UND-I-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia in Chronic Kidney Diseases
-
Astellas Pharma Europe B.V.FibroGenCompletedAnemia in Chronic Kidney Disease in Non-dialysis PatientsSpain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
-
Astellas Pharma Europe B.V.FibroGenCompletedAnemia in Chronic Kidney Disease in Non-dialysis PatientsAustria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain and more
-
FibroGenCompletedAnemia in Chronic Kidney DiseaseChina
-
Astellas Pharma IncCompletedAnemia in Chronic Kidney Disease Patients Not on DialysisJapan
-
FerruMax Pharmaceuticals, Inc.TerminatedAnemia in Chronic Kidney DiseaseUnited States
-
FibroGenCompletedCKD Anemia in Dialysis ParticipantsChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.Fifth Affiliated Hospital of Guangzhou Medical UniversityRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
AmgenCompletedAnemia in Chronic Kidney Disease Patients Not on DialysisUnited States, Puerto Rico
-
Shengzhen Sciprogen Bio-pharmaceutical Co. LtdUnknownPatient of Anemia in Chronic Renal Failure With HemodialysisChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States